PF-Atlas › Clinical Trials › NCT07919015

Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

Nerandomilast · Not specified

Registry ID
NCT07919015
Phase
Not specified
Status
Recruiting
Drug / intervention
Nerandomilast
Sponsor
Avraham Unterman
Enrollment
70
Locations
4

About this trial

Nerandomilast is an oral medicine that slows down the loss of functional residual capacity (FVC) in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It was tested in two large clinical trials in which participants were carefully selected. In everyday practice, patients are often older, have more other illnesses, or take additional medicines, and it is not known whether the benefits seen in the trials also occur outside them. The Real-world Study of Nerandomilast (ReaSoN-IPF/PPF) follows people with IPF or PPF who begin nerandomilast as part of their usual medical care at several medical centers in Israel. The study does not assign any treatment; the treating physician makes every decision about therapy. The main goal is to find out whether lung fu

View NCT07919015 on ClinicalTrials.gov →

Medical disclaimer. This page summarizes public trial data for NCT07919015 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.